Zoetis Inc. $ZTS Stock Holdings Lifted by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC raised its position in Zoetis Inc. (NYSE:ZTS) by 14.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,714 shares of the company’s stock after purchasing an additional 13,211 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Zoetis were worth $16,642,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Brighton Jones LLC grew its stake in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Merit Financial Group LLC grew its stake in Zoetis by 62.3% in the first quarter. Merit Financial Group LLC now owns 12,178 shares of the company’s stock valued at $2,005,000 after purchasing an additional 4,676 shares in the last quarter. Vest Financial LLC purchased a new position in Zoetis in the first quarter valued at about $207,000. Intellectus Partners LLC grew its stake in Zoetis by 19.6% in the first quarter. Intellectus Partners LLC now owns 6,849 shares of the company’s stock valued at $1,128,000 after purchasing an additional 1,121 shares in the last quarter. Finally, IAM Advisory LLC grew its stake in Zoetis by 0.8% in the first quarter. IAM Advisory LLC now owns 10,102 shares of the company’s stock valued at $1,663,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $146.45 on Friday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market capitalization of $64.91 billion, a PE ratio of 25.21, a P/E/G ratio of 2.35 and a beta of 0.90. The stock has a 50-day simple moving average of $149.79 and a 200 day simple moving average of $155.14.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the previous year, the firm earned $1.56 EPS. The firm’s revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZTS shares. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.